Utilizing novel fluorothymidine PET imaging in a phase I study of veliparib on an intermittent and continuous schedule given in combination with carboplatin in metastatic breast cancer
Robert Wesolowski, View ORCID ProfileDaniel G. Stover, Maryam B. Lustberg, Abigail Shoben, Meng Zhao, Ewa Mrozek, Rachel M. Layman, Erin Macrae, Wenrui Duan, Jun Zhang, Nathan Hall, Chadwick L. Wright, Katharina Schregel, Susan Gillespie, Michael Berger, Andrea Camp, Jeffrey J. Chalmers, Priya Balasubramanian, Brandon L. Miller, Peter Amaya, Eleni Andreopoulou, Joseph Sparano, Charles L. Shapiro, Miguel Angel Villalona-Calero, Susan Geyer, Alice Chen, Michael R. Grever, Michael V Knopp, Bhuvaneswari Ramaswamy
doi: https://doi.org/10.1101/2020.01.20.20018218
Robert Wesolowski
1Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
Daniel G. Stover
1Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
Maryam B. Lustberg
1Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH
Abigail Shoben
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
Meng Zhao
1Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH
Ewa Mrozek
3Mercy Health – St. Rita’s Medical Center, Lima, OH
Rachel M. Layman
4University of Texas MD Anderson Cancer Center, Houston, TX
Erin Macrae
5Columbus Oncology, Columbus, OH
Wenrui Duan
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
Jun Zhang
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
Nathan Hall
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
Chadwick L. Wright
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
Katharina Schregel
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
Susan Gillespie
1Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH
Michael Berger
1Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH
Andrea Camp
1Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH
Jeffrey J. Chalmers
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
Priya Balasubramanian
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
Brandon L. Miller
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
Peter Amaya
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
Eleni Andreopoulou
6Weill Cornell Medicine, New York, NY
Joseph Sparano
7Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
Charles L. Shapiro
8Tisch Cancer Institute, Mt. Sinai Hospital, New York, NY
Miguel Angel Villalona-Calero
9Miami Cancer Institute, Baptist Health South Florida, Miami, FL
Susan Geyer
10University of South Florida, Tampa, FL
Alice Chen
11National Cancer Institute, Bethesda, MD
Michael R. Grever
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
Michael V Knopp
2The Ohio State University Comprehensive Cancer Center, Columbus, OH
Bhuvaneswari Ramaswamy
1Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH
Article usage
Posted January 24, 2020.
Utilizing novel fluorothymidine PET imaging in a phase I study of veliparib on an intermittent and continuous schedule given in combination with carboplatin in metastatic breast cancer
Robert Wesolowski, Daniel G. Stover, Maryam B. Lustberg, Abigail Shoben, Meng Zhao, Ewa Mrozek, Rachel M. Layman, Erin Macrae, Wenrui Duan, Jun Zhang, Nathan Hall, Chadwick L. Wright, Katharina Schregel, Susan Gillespie, Michael Berger, Andrea Camp, Jeffrey J. Chalmers, Priya Balasubramanian, Brandon L. Miller, Peter Amaya, Eleni Andreopoulou, Joseph Sparano, Charles L. Shapiro, Miguel Angel Villalona-Calero, Susan Geyer, Alice Chen, Michael R. Grever, Michael V Knopp, Bhuvaneswari Ramaswamy
medRxiv 2020.01.20.20018218; doi: https://doi.org/10.1101/2020.01.20.20018218
Utilizing novel fluorothymidine PET imaging in a phase I study of veliparib on an intermittent and continuous schedule given in combination with carboplatin in metastatic breast cancer
Robert Wesolowski, Daniel G. Stover, Maryam B. Lustberg, Abigail Shoben, Meng Zhao, Ewa Mrozek, Rachel M. Layman, Erin Macrae, Wenrui Duan, Jun Zhang, Nathan Hall, Chadwick L. Wright, Katharina Schregel, Susan Gillespie, Michael Berger, Andrea Camp, Jeffrey J. Chalmers, Priya Balasubramanian, Brandon L. Miller, Peter Amaya, Eleni Andreopoulou, Joseph Sparano, Charles L. Shapiro, Miguel Angel Villalona-Calero, Susan Geyer, Alice Chen, Michael R. Grever, Michael V Knopp, Bhuvaneswari Ramaswamy
medRxiv 2020.01.20.20018218; doi: https://doi.org/10.1101/2020.01.20.20018218
Subject Area
Subject Areas
- Addiction Medicine (390)
- Allergy and Immunology (705)
- Anesthesia (195)
- Cardiovascular Medicine (2874)
- Dermatology (244)
- Emergency Medicine (432)
- Epidemiology (12597)
- Forensic Medicine (10)
- Gastroenterology (809)
- Genetic and Genomic Medicine (4470)
- Geriatric Medicine (405)
- Health Economics (717)
- Health Informatics (2865)
- Health Policy (1056)
- Hematology (378)
- HIV/AIDS (905)
- Medical Education (418)
- Medical Ethics (115)
- Nephrology (465)
- Neurology (4226)
- Nursing (226)
- Nutrition (619)
- Oncology (2215)
- Ophthalmology (629)
- Orthopedics (255)
- Otolaryngology (321)
- Pain Medicine (269)
- Palliative Medicine (83)
- Pathology (488)
- Pediatrics (1181)
- Primary Care Research (485)
- Public and Global Health (6810)
- Radiology and Imaging (1499)
- Respiratory Medicine (904)
- Rheumatology (430)
- Sports Medicine (372)
- Surgery (474)
- Toxicology (59)
- Transplantation (204)
- Urology (175)